<DOC>
	<DOC>NCT00837356</DOC>
	<brief_summary>This trial is conducted in Europe and Asia. The aim of this clinical trial is to compare two recombinant factor VIII drugs, turoctocog alfa (recombinant factor VIII (N8)) with Advate®, in haemophilia A subjects, investigating the action and safety of the drugs.</brief_summary>
	<brief_title>Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe haemophilia A (FVIII level less than or equal to 1%) Treatment history of more than 150 exposure days with recombinant or plasmaderived FVIII replacement products HIV or HCV negative, or if positive the patient is on a stable antiviral regimen at the time of the enrolment in the trial Presence of any bleeding disorder in addition to haemophilia A Inhibitor titre greater than or equal to 0.6 Bethesda Units (BU) at screening and past history of inhibitor Abnormal renal function tests Known hypersensitivity to Advate®</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>